Study on Anticoagulant Treatment for Portal Vein Thrombosis in Cirrhosis Patients
Objective
To compare the safety and effectiveness of two anticoagulant treatments for portal vein thrombosis (PVT) in cirrhosis patients.
Methods
Cirrhotic patients with PVT received low-molecular-weight heparin calcium (LMWH-Ca) injections for 2 weeks. They were then randomly assigned to receive either warfarin or rivaroxaban for a specified duration. Volumetric changes in PVT were monitored using computed tomography scans.
Results
Rivaroxaban treatment significantly reduced PVT volume and prevented worsening, while warfarin treatment led to an increase in PVT volume. Rivaroxaban also showed a lower incidence of gastrointestinal bleeding compared to warfarin.
Conclusion
Rivaroxaban followed by LMWH-Ca is an effective anticoagulant treatment strategy for PVT in cirrhosis.
Value of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research, making valuable knowledge easily accessible to clinicians.
Practical Solutions
Our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining operations and expanding digital services in healthcare.
AI Integration for Improved Workflows
By leveraging AI, clinics can enhance workflows, improve patient outcomes, and reduce paper-based routines. Learn more about our solutions at aidevmd.com.
